Investors Alert: Class Action Lawsuit Filed Against aTyr Pharma, Inc. Amidst Falling Stock Prices

Pomerantz Law Firm Issues Investor Alert on aTyr Pharma

The Pomerantz Law Firm has recently announced a class action lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR), following a major drop in the company’s stock price after disappointing clinical trial results. Investors who have incurred losses due to their investment in aTyr are being advised to reach out to the firm to get involved in the ongoing legal proceedings.

Background on the Case

The lawsuit pertains to accusations that aTyr and certain executives may have committed securities fraud or engaged in other unlawful business practices. In particular, the investigation focuses on the events surrounding the company's recent announcement regarding their EFZO-FIT study. This Phase 3 study was designed to evaluate the safety and effectiveness of intravenous Efzofitimod for patients suffering from pulmonary sarcoidosis.

On September 15, 2025, aTyr disclosed that the EFZO-FIT study failed to meet its primary efficacy endpoint, leading to an 83.17% decline in stock price, dropping from approximately $6.02 to $1.01 per share. This significant decrease raised alarms among shareholders and initiated the class action suit.

Next Steps for Investors

For those who acquired aTyr’s securities during the specified Class Period, the deadline to file a motion with the court to serve as the Lead Plaintiff is December 8, 2025. Interested parties are encouraged to contact Danielle Peyton at Pomerantz LLP, as those who communicate via email should include their contact details and the number of shares purchased. A copy of the complaint is also accessible at www.pomerantzlaw.com.

Pomerantz’s History and Commitment

Pomerantz LLP is recognized as one of the leading law firms in corporate, securities, and antitrust class litigations. Established over 85 years ago by Abraham L. Pomerantz, the firm has an exemplary track record of standing up for the rights of victims of securities fraud and corporate misconduct. They have successfully secured numerous multimillion-dollar awards for class members, demonstrating their commitment to justice and accountability in the financial sector.

Conclusion

As aTyr Pharma navigates through this challenging period, investors should stay informed about their rights and the developments within the lawsuit. The Pomerantz Law Firm stands ready to assist those impacted by this situation in seeking recovery for their losses. Investors are reminded that prior results do not guarantee similar outcomes, and legal proceedings can be complex, warranting careful consideration and professional assistance.

For more information and subsequent updates, stakeholders can visit the Pomerantz Law Firm’s website or contact their office directly.